Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool.

Bellan SE, Eggo RM, Gsell PS, Kucharski AJ, Dean NE, Donohue R, Zook M, Edmunds WJ, Odhiambo F, Longini IM Jr, Brisson M, Mahon BE, Henao-Restrepo AM.

Vaccine. 2019 Jul 18;37(31):4376-4381. doi: 10.1016/j.vaccine.2019.06.019. Epub 2019 Jun 24.

2.

Downgrading disease transmission risk estimates using terminal importations.

Fox SJ, Bellan SE, Perkins TA, Johansson MA, Meyers LA.

PLoS Negl Trop Dis. 2019 Jun 14;13(6):e0007395. doi: 10.1371/journal.pntd.0007395. eCollection 2019 Jun.

3.

Evaluation of alternative endpoints for ZIKV vaccine efficacy trials.

Mercaldo RA, Bellan SE.

Vaccine. 2019 Apr 3;37(15):2099-2105. doi: 10.1016/j.vaccine.2019.02.066. Epub 2019 Mar 11.

PMID:
30871928
4.

Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection.

Kahn R, Hitchings M, Wang R, Bellan SE, Lipsitch M.

Am J Epidemiol. 2019 Feb 1;188(2):467-474. doi: 10.1093/aje/kwy239.

PMID:
30329134
5.

Couple serostatus patterns in sub-Saharan Africa illuminate the relative roles of transmission rates and sexual network characteristics in HIV epidemiology.

Bellan SE, Champredon D, Dushoff J, Meyers LA.

Sci Rep. 2018 Apr 27;8(1):6675. doi: 10.1038/s41598-018-24249-7.

6.
7.

Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials.

Hitchings MDT, Lipsitch M, Wang R, Bellan SE.

Am J Epidemiol. 2018 Aug 1;187(8):1763-1771. doi: 10.1093/aje/kwy047.

8.

Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.

Kahn R, Hitchings M, Bellan S, Lipsitch M.

Clin Trials. 2018 Apr;15(2):207-211. doi: 10.1177/1740774517752671. Epub 2018 Jan 27.

9.

Simulations for designing and interpreting intervention trials in infectious diseases.

Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, Cooper BS, DeGruttola V, Hughes JP, Lessler J, Lofgren ET, Longini IM, Onnela JP, Özler B, Seage GR, Smith TA, Vespignani A, Vynnycky E, Lipsitch M.

BMC Med. 2017 Dec 29;15(1):223. doi: 10.1186/s12916-017-0985-3.

10.

Resource-driven encounters among consumers and implications for the spread of infectious disease.

Borchering RK, Bellan SE, Flynn JM, Pulliam JRC, McKinley SA.

J R Soc Interface. 2017 Oct;14(135). pii: 20170555. doi: 10.1098/rsif.2017.0555.

11.

Early antiretroviral therapy and potent second-line drugs could decrease HIV incidence of drug resistance.

Shen M, Xiao Y, Rong L, Meyers LA, Bellan SE.

Proc Biol Sci. 2017 Jun 28;284(1857). pii: 20170525. doi: 10.1098/rspb.2017.0525.

12.

Assessing real-time Zika risk in the United States.

Castro LA, Fox SJ, Chen X, Liu K, Bellan SE, Dimitrov NB, Galvani AP, Meyers LA.

BMC Infect Dis. 2017 May 4;17(1):284. doi: 10.1186/s12879-017-2394-9.

13.

Correction: Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database.

Means AR, Risher KA, Ujeneza EL, Maposa I, Nondi J, Bellan SE.

PLoS One. 2017 Jan 6;12(1):e0170155. doi: 10.1371/journal.pone.0170155. eCollection 2017.

14.

Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database.

Means AR, Risher KA, Ujeneza EL, Maposa I, Nondi J, Bellan SE.

PLoS One. 2016 Oct 7;11(10):e0164148. doi: 10.1371/journal.pone.0164148. eCollection 2016. Erratum in: PLoS One. 2017 Jan 6;12 (1):e0170155.

15.

Reevaluating Cumulative HIV-1 Viral Load as a Prognostic Predictor: Predicting Opportunistic Infection Incidence and Mortality in a Ugandan Cohort.

Sempa JB, Dushoff J, Daniels MJ, Castelnuovo B, Kiragga AN, Nieuwoudt M, Bellan SE.

Am J Epidemiol. 2016 Jul 1;184(1):67-77. doi: 10.1093/aje/kwv303. Epub 2016 May 4.

16.

Evaluating Ebola vaccine trials: insights from simulation.

Pulliam JRC, Bellan SE, Gambhir M, Meyers LA, Dushoff J.

Lancet Infect Dis. 2015 Oct;15(10):1134. doi: 10.1016/S1473-3099(15)00303-5. Epub 2015 Sep 20. No abstract available.

17.

The effect of sexually transmitted co-infections on HIV viral load amongst individuals on antiretroviral therapy: a systematic review and meta-analysis.

Champredon D, Bellan SE, Delva W, Hunt S, Shi CF, Smieja M, Dushoff J.

BMC Infect Dis. 2015 Jun 30;15:249. doi: 10.1186/s12879-015-0961-5. Review.

18.

Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis.

Bellan SE, Pulliam JR, Pearson CA, Champredon D, Fox SJ, Skrip L, Galvani AP, Gambhir M, Lopman BA, Porco TC, Meyers LA, Dushoff J.

Lancet Infect Dis. 2015 Jun;15(6):703-10. doi: 10.1016/S1473-3099(15)70139-8. Epub 2015 Apr 14.

19.

Reassessment of HIV-1 acute phase infectivity: accounting for heterogeneity and study design with simulated cohorts.

Bellan SE, Dushoff J, Galvani AP, Meyers LA.

PLoS Med. 2015 Mar 17;12(3):e1001801. doi: 10.1371/journal.pmed.1001801. eCollection 2015 Mar.

20.

Ebola virus vaccine trials: the ethical mandate for a therapeutic safety net.

Bellan SE, Pulliam JR, Dushoff J, Meyers LA.

BMJ. 2014 Dec 10;349:g7518. doi: 10.1136/bmj.g7518. No abstract available.

21.

Ebola control: effect of asymptomatic infection and acquired immunity.

Bellan SE, Pulliam JR, Dushoff J, Meyers LA.

Lancet. 2014 Oct 25;384(9953):1499-500. doi: 10.1016/S0140-6736(14)61839-0. Epub 2014 Oct 15. No abstract available.

22.

Frequent and seasonally variable sublethal anthrax infections are accompanied by short-lived immunity in an endemic system.

Cizauskas CA, Bellan SE, Turner WC, Vance RE, Getz WM.

J Anim Ecol. 2014 Sep;83(5):1078-90. doi: 10.1111/1365-2656.12207. Epub 2014 Mar 14.

23.

Failure of Sterne- and Pasteur-like strains of Bacillus anthracis to replicate and survive in the urban bluebottle blow fly Calliphora vicina under laboratory conditions.

von Terzi B, Turnbull PC, Bellan SE, Beyer W.

PLoS One. 2014 Jan 2;9(1):e83860. doi: 10.1371/journal.pone.0083860. eCollection 2014.

24.

HIV sexual transmission is predominantly driven by single individuals rather than discordant couples: a model-based approach.

Champredon D, Bellan S, Dushoff J.

PLoS One. 2013 Dec 20;8(12):e82906. doi: 10.1371/journal.pone.0082906. eCollection 2013.

25.

A Hierarchical Distance Sampling Approach to Estimating Mortality Rates from Opportunistic Carcass Surveillance Data.

Bellan SE, Gimenez O, Choquet R, Getz WM.

Methods Ecol Evol. 2013 Apr 1;4(4). doi: 10.1111/2041-210x.12021.

26.

Effects of experimental exclusion of scavengers from carcasses of anthrax-infected herbivores on Bacillus anthracis sporulation, survival, and distribution.

Bellan SE, Turnbull PC, Beyer W, Getz WM.

Appl Environ Microbiol. 2013 Jun;79(12):3756-61. doi: 10.1128/AEM.00181-13. Epub 2013 Apr 12.

27.

Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data.

Bellan SE, Fiorella KJ, Melesse DY, Getz WM, Williams BG, Dushoff J.

Lancet. 2013 May 4;381(9877):1561-9. doi: 10.1016/S0140-6736(12)61960-6. Epub 2013 Feb 5.

28.

How to make epidemiological training infectious.

Bellan SE, Pulliam JR, Scott JC, Dushoff J; MMED Organizing Committee.

PLoS Biol. 2012;10(4):e1001295. doi: 10.1371/journal.pbio.1001295. Epub 2012 Apr 3.

29.

Black-backed jackal exposure to rabies virus, canine distemper virus, and Bacillus anthracis in Etosha National Park, Namibia.

Bellan SE, Cizauskas CA, Miyen J, Ebersohn K, Küsters M, Prager KC, Van Vuuren M, Sabeta C, Getz WM.

J Wildl Dis. 2012 Apr;48(2):371-81.

30.

Distribution and molecular evolution of bacillus anthracis genotypes in Namibia.

Beyer W, Bellan S, Eberle G, Ganz HH, Getz WM, Haumacher R, Hilss KA, Kilian W, Lazak J, Turner WC, Turnbull PC.

PLoS Negl Trop Dis. 2012;6(3):e1534. doi: 10.1371/journal.pntd.0001534. Epub 2012 Mar 6.

31.

Estimating carnivoran diets using a combination of carcass observations and scats from GPS clusters.

Tambling CJ, Laurence SD, Bellan SE, Cameron EZ, du Toit JT, Getz WM.

J Zool (1987). 2012 Feb 1;286(2):102-109.

32.
33.

[On the activity of mucopolysaccharidases administered rectally].

Brustier V, Podesta M, Bellan S, Amselem A, Nang LS.

Farmaco Prat. 1969 Apr;24(4):203-14. French. No abstract available.

PMID:
4239692

Supplemental Content

Loading ...
Support Center